Product Information
BUPROPION HCL XL 300 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $0.1004 per EA under NDC 45963014205. Its NADAC has been published 591 times since Jun 10, 2015.
FDA first approved this application on Aug 15, 2008. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
45963014205
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUPROPION HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077285FDA Approved
8/15/2008
TE Code
AB3
On Market Since
2/17/2015
Pharmacological Classes
Price Statistics
The NADAC for BUPROPION HCL XL 300 MG TABLET has been published 591 times since Jun 10, 2015, and over the history we have for it it has declined 86.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1004 per EA |
|---|---|
| All-time high | $0.7543 (Aug 12, 2015) |
| All-time low | $0.1004 (Sep 23, 2026) |
| 52-week high | $0.1461 |
| 52-week low | $0.1004 |
| Median price | $0.2221 |
| Average price | $0.3030 |
| Largest weekly change | -33.9% (Sep 18, 2019) |
| Weeks tracked | 591 |
| Tracking since | Jun 10, 2015 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Bupropion Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoketone class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPROPION HCL XL 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUPROPION HCL XL 300 MG TABLET, manufactured by Actavis Pharma, Inc., is $0.1004 per EA (NDC 45963014205), effective Sep 30, 2026.
How has the price of BUPROPION HCL XL 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUPROPION HCL XL 300 MG TABLET has declined 86.3%. It has been tracked across 591 weekly CMS publications since Jun 10, 2015.
What are the highest and lowest recorded NADAC prices for BUPROPION HCL XL 300 MG TABLET?
Since Jun 10, 2015, the NADAC for BUPROPION HCL XL 300 MG TABLET has ranged from a low of $0.1004 (Sep 23, 2026) to a high of $0.7543 (Aug 12, 2015), with a median of $0.2221 per EA.
Are there cheaper alternatives to BUPROPION HCL XL 300 MG TABLET?
9 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUPROPION HCL XL 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures BUPROPION HCL XL 300 MG TABLET?
BUPROPION HCL XL 300 MG TABLET (NDC 45963014205) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.